Skip to content

News

Filipe Pereira, co-founder of Asgard Therapeutics, awarded with a BII PreSeed grant

The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.
Read More

Asgard Therapeutics awarded Vinnova’s Innovative Startup Step 2

Swedish start-up company Asgard Therapeutics has been awarded the second step of Vinnova’s Innovative Startup program in order to further develop a new cancer immunotherapy based on dendritic cell reprogramming.
Read More

Asgard Therapeutics awarded with Lund University Innovation VFT+ Funds

Asgard was selected to receive Vinnova’s VFT+ funds managed by LU Innovation for verification activities of TrojanDC towards partners, customers and investors. 
Read More

Fábio Rosa, co-founder of Asgard Therapeutics, selected for Forbes 30 under 30 List – Europe – Science & Healthcare 2020

Fábio Rosa, co-founder of Asgard Therapeutics, was selected by Forbes among 30 brightest young entrepreneurs, innovators and game changers in Science and Healthcare segment. https://www.forbes.com/profile/fabio-rosa/#7376307670f8
Read More

Filipe Pereira, co-founder of Asgard Therapeutics, awarded with European Research Council (ERC) Consolidator Grant

The European Research Council (ERC) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with an ERC Consolidator Grant to harness dendritic cell reprogramming towards the development of new patient-specific strategies for
Read More

Asgard Therapeutics wins NOME entrepreneurship competition

Asgard Therapeutics won the Nordic Mentor Network for Entrepreneurship (NOME) Nordic entrepreneurship competition for promising life science companies and becomes part of the Novo Nordisk-funded NOME mentoring network.
Read More

Asgard Therapeutics awarded H2020 SMEi phase 1

Swedish start-up company Asgard Therapeutics has been awarded H2020 SMEi phase 1 in order to further develop a direct cell reprogramming technology for cancer immunotherapy. Asgard Therapeutics was founded in
Read More

Cristiana Pires, CEO and co-founder of Asgard Therapeutics, receives Audience choice Award at BIOEurope Start-up Slam

Cristiana Pires, CEO and co-founder of Asgard Therapeutics, awarded with ‘Audience Choice’ Award at BIOEurope Start-up Slam pitch competition promoted by J&J Innovation – JLabs. https://www.ebdgroup.com/bio-europe-2019s-startup-slam-winner-eisbach-bio/
Read More

Asgard Therapeutics wins Sten K Johnson Grant

Asgard Therapeutics won the Sten K Johnson Grant in the category of Medicine for projects with innovative ideas of medical importance that challenge traditional methods and concepts.
Read More

Asgard Therapeutics awarded with Lund University Innovation IKS Accelerator grant 2019

Asgard Therapeutics was awarded with Lund University Innovation IKS Accelerator grant 2019.
Read More

Asgard Therapeutics awarded Novo Seeds Exploratory Pre-seed Grant

Asgard Therapeutics has been awarded Novo Seeds Exploratory Pre-seed Grant to develop dendritic cell reprogramming as a new approach for cancer immunotherapy.
Read More

Asgard Therapeutics awarded with Lund University Innovation VFT Funds

Asgard Therapeutics was awarded with Lund University Innovation VFT Funds for verification activities of the project Reprogramming of Fibroblasts into Antigen-Presenting Dendritic Cells towards partners, customers and investors.
Read More